BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 24215406)

  • 21. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
    Song IH; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Weiß A; Buß B; Freundlich B; Lange E; Alten R; Rudwaleit M; Sieper J
    J Rheumatol; 2014 Oct; 41(10):2034-40. PubMed ID: 25028375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
    Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
    J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
    Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
    Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
    Baraliakos X; Kiltz U; Peters S; Appel H; Dybowski F; Igelmann M; Kalthoff L; Krause D; Menne HJ; Saracbasi-Zender E; Schmitz-Bortz E; Vigneswaran M; Braun J
    Rheumatology (Oxford); 2017 Jan; 56(1):95-102. PubMed ID: 27997346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
    Haibel H; Rudwaleit M; Listing J; Heldmann F; Wong RL; Kupper H; Braun J; Sieper J
    Arthritis Rheum; 2008 Jul; 58(7):1981-91. PubMed ID: 18576337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
    Poddubnyy D; Rudwaleit M
    Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
    Paccou J; Flipo RM
    Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.
    Gremese E; Bernardi S; Bonazza S; Nowik M; Peluso G; Massara A; Tolusso B; Messuti L; Miceli MC; Zoli A; Trotta F; Govoni M; Ferraccioli G
    Rheumatology (Oxford); 2014 May; 53(5):875-81. PubMed ID: 24407233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.
    Deodhar A; Strand V; Kay J; Braun J
    Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
    Dougados M; van der Heijde D; Sieper J; Braun J; Maksymowych WP; Citera G; Miceli-Richard C; Wei JC; Pedersen R; Bonin R; Rahman MU; Logeart I; Wajdula J; Koenig AS; Vlahos B; Alvarez D; Bukowski JF
    Arthritis Rheumatol; 2014 Aug; 66(8):2091-102. PubMed ID: 24891317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of radiographic progression at two years in a cohort of patients with non-radiographic axial spondyloarthritis treated with TNF-α blockers.
    Almirall M; López-Velandia JG; Maymó J
    Reumatol Clin; 2014; 10(2):134-5. PubMed ID: 23827199
    [No Abstract]   [Full Text] [Related]  

  • 37. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASAS classification criteria for axial spondyloarthritis: time to modify.
    Akkoc N; Khan MA
    Clin Rheumatol; 2016 Jun; 35(6):1415-23. PubMed ID: 27094940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis.
    Olivieri I; D'Angelo S; Palazzi C; Leccese P; Nigro A; Padula A
    Reumatismo; 2013 Mar; 65(1):1-3. PubMed ID: 23550255
    [No Abstract]   [Full Text] [Related]  

  • 40. Certolizumab pegol.
    Melmed GY; Targan SR; Yasothan U; Hanicq D; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Aug; 7(8):641-2. PubMed ID: 18670430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.